BioGrowth Inc. has received a $225,000 Phase II smallbusiness innovation research grant from the U.S. Department ofAgriculture to study ways of developing agricultural animalswith more lean meat and less fat.

The grant will allow BioGrowth of Richmond, Calif., to beginproduction of insulin-like growth factor (IGF-I) and bovine IGFbinding protein-3, and to test those proteins in bovine, porcineand avian animal models.

IGF-I is an anabolic product that helps animals put on morelean mass and less fat. The binding protein extends the half-life of IGF-I and improves its efficacy and safety, said EdwardLanphier II, BioGrowth's president and chief executive officer.

"This is a new and small part of our activities," said Lanphier.BioGrowth's primary focus is on human therapeutics. Thecompany's most advanced program is developing IGF-I and IGFbinding protein-3 to treat osteoporosis, topical and systemictissue repair, and nutritional deficiencies. These indicationsare in animal studies. BioGrowth is also developing bindingproteins for interleukin-1 and epidermal growth factor. --Karen Bernstein

(c) 1997 American Health Consultants. All rights reserved.